✦ LIBER ✦

Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes

✍ Scribed by Harold J. Olney; Michelle M. Le Beau

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 262 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.10.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The treatment of the myelodysplastic syn

The treatment of the myelodysplastic syndromes

✍ Harvey D. Preisler 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 2 views

T he article by Ferrara et al. 1 in this issue of Cancer describes the treatment of patients with poor prognosis myelodysplastic syndromes (MDS) using intensive remission induction chemotherapy followed by peripheral blood stem cell transplantation for patients age Ͻ 60 years. Thirty-two patients wi

Distribution of cytogenetic abnormalitie

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category

✍ Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Tamara Weiss; Torsten Haferlac 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 134 KB

Unique cytogenetic features of primary m

Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients

✍ Lin Li; Xu-Ping Liu; Ling Nie; Ming-Hua Yu; Yue Zhang; Tie-Jun Qin; Zhi-Jian Xia 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 257 KB

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms. Chromosomal abnormalities have been detected in 40-70% patients with primary MDS and are heterogeneous among patients of different races and from different backgrounds. In the current study, 351 Chinese adult patients wi

The prognostic value of maturation-assoc

The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes

✍ I. Lorand-Metze; S.M.V. Califani; E. Ribeiro; C.S.P. Lima; K. Metze 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Several phenotypic abnormalities of bone marrow (BM) hemopoietic precursors have been associated with disease progression in myelodysplastic syndromes (MDS). We analyzed the influence on overall survival of the expression of lineage and maturation-associated antigens of BM hemopoietic cells quantifi

Evaluation of continuous infusion low-do

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes

✍ Dr. Christopher R. Chitambar; Joseph A. Libnoch; William G. Matthaeus; Robert C. 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB 👁 2 views

Deletions of CDKN1B and ETV6 in acute my

Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities

✍ Patrik Andreasson; Bertil Johansson; Kristina Arheden; Rolf Billström; Felix Mit 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 2 views

Seventy-nine acute myeloid leukemias (AML) and myelodysplastic syndromes without cytogenetic evidence of 12p aberrations were investigated by fluorescence in situ hybridization with probes for ETV6 and CDKN1B (previously called TEL and KIP1, respectively) to ascertain whether abnormalities of these